Document is current

Article History

Received: 7 November 2023

Accepted: 23 March 2024

First Online: 17 April 2024

Declarations

:

: This study was approved by the London-West London and GTAC ethics committee (Integrated Research Application System reference: 209761, study reference 16/LO/1941) and the Administration of Radioactive Substances Advisory Committee (ARSAC, UK). All methods were carried out in accordance with the updated Declaration of Helsinki (2013).

: All participants received a description of the study prior to providing written informed consent to participate and for their data to be used as part of the study.

: Not applicable.

: Oliver Howes was previously a part-time employee of H Lundbeck A/s. He has received investigator-initiated research funding from and/or participated in advisory/ speaker meetings organised by Angellini, Autifony, Biogen, Boehringer-Ingelheim, Eli Lilly, Heptares, Global Medical Education, Invicro, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Recordati, Roche and Viatris/ Mylan. Neither Dr Howes nor his family have holdings/ a financial stake in any pharmaceutical company. Dr Howes has a patent for the use of dopaminergic imaging. Ilan Rabiner, Matt Wall, Gaia Rizzo, Ayla Mansur are all employees or past employees of Invicro London. Hideo Tsukada is an employee of Hamamatsu Photonics, Japan. Tiago Reis Marques is an employee and founder of Pasithea Therapeutics. Other authors have reported no biomedical financial interests or potential conflicts of interest.